



UNIVERSITI PUTRA MALAYSIA

**PROTECTIVE EFFICACY EVALUATION OF NP_t-VP11-100 PROTEIN
AS A CANDIDATE VACCINE AGAINST ENTEROVIRUS 71
INFECTIONS IN MOUSE MODEL**

CH'NG WEI CHOONG

FBSB 2010 21



**PROTECTIVE EFFICACY EVALUATION OF NPt-VP1₁₋₁₀₀ PROTEIN AS
A CANDIDATE VACCINE AGAINST ENTEROVIRUS 71 INFECTIONS
IN MOUSE MODEL**

By

CH'NG WEI CHOONG

**Thesis Submitted to the School of Graduate Studies, Universiti Putra Malaysia,
in Fulfilment of the Requirements for the Degree of Master of Science**

June 2010



Abstract of thesis presented to the Senate of Universiti Putra Malaysia in fulfilment of the requirement for the degree of Master of Science

**PROTECTIVE EFFICACY EVALUATION OF NPt-VP1₁₋₁₀₀ PROTEIN AS
A CANDIDATE VACCINE AGAINST ENTEROVIRUS 71 INFECTIONS
IN MOUSE MODEL**

By

CH'NG WEI CHOONG

June 2010

Chairman: Norazizah Shafee, PhD

Faculty: Biotechnology and Biomolecular Sciences

Enterovirus 71 (EV71) is a type of human virus belonging to the *Enterovirus* genus within the *Picornaviridae* family. The virus mainly causes hand, foot and mouth disease in children which sometimes lead to severe neurological complications. Outbreaks of EV71 infections are serious health threats since effective antiviral drugs or vaccines are not currently available. Therefore, development of an effective vaccine is ideal for the prevention and control of EV71 disease outbreak. The use of recombinant EV71 viral protein offers an alternative to the more risky method of using whole live attenuated or inactivated virus. Our previous study using truncated VP1 protein (VP1₁₋₁₀₀) of EV71 virus fused to a carrier protein showed strong immune response in adult rabbits. The study however, did not address the issue of its effectiveness in young animals. This factor is important since EV71 mostly infected children younger than 5 year-old. In the present study, we investigated the protective



efficacy of NPt-VP1₁₋₁₀₀ protein against EV71 infection in a recently-developed newborn mouse model system. Prior to investigation in the newborn mouse model, we evaluated the type of immune responses developed by adult mice against NPt-VP1₁₋₁₀₀ protein. In adult mice, the protein induced high levels of anti-VP1 IgG production. Purified VP1 antigen stimulated activation, proliferation and differentiation of splenocytes harvested from the immunized mice. They also produced high levels of IFN- γ . Following determination of immune responses towards NPt-VP1₁₋₁₀₀ protein in adult mice, we performed immunization and virus challenge study in newborn mice model. Since the mice was only susceptible to EV71 infection before they are 14 day-old, only two doses of immunization were carried out. Even though the IgG produced lacked neutralization properties, immunized newborn mice were still partially protected from EV71 viral challenge. They showed high (47.4%) survival rate as compared to the control group and importantly, 50% of them fully recovered from paralysis symptoms at the end of the study. Histological analysis of all the surviving mice revealed a complete clearance of EV71 viral antigens from their brains and spinal cords. In hind limb muscles, the level of antigens detected correlated directly with tissue damage and their paralysis symptoms. We also initiated a similar study in a hamster model which had longer EV71 susceptibility period. In hamster, the NPt-VP1₁₋₁₀₀ protein was also found to be highly immunogenic. Findings from the study showed that immunization with NPt-VP1₁₋₁₀₀ protein in newborn mice model confer them a partial protection against EV71 infection. NPt-VP1₁₋₁₀₀ protein therefore offers a great promise towards finding a vaccine for EV71 infections.



Abstrak tesis yang dikemukakan kepada Senat Universiti Putra Malaysia sebagai memenuhi keperluan untuk ijazah Master Sains

**PENILAIAN TERHADAP KEBERKESANAN PERLINDUNGAN PROTEIN
NPt-VP1₁₋₁₀₀ SEBAGAI SATU CALON VAKSIN UNTUK JANGKITAN
ENTEROVIRUS 71 DALAM MODEL MENCIT**

Oleh

CH'NG WEI CHOONG

Jun 2010

Pengerusi: Norazizah Shafee, PhD

Fakulti: Bioteknologi dan Sains Biomolekul

Enterovirus 71 (EV71) adalah sejenis virus manusia yang tergolong dalam genus *Enterovirus* dan famili *Picornaviridae*. Virus ini merupakan penyebab penyakit tangan, kaki dan mulut di kalangan kanak-kanak dan ia boleh menyebabkan komplikasi neurologi yang teruk. Wabak jangkitan EV71 merupakan ancaman kesihatan yang serius kerana sehingga kini, tiada ubat atau vaksin antivirus yang berkesan untuk merawat dan mencegah penyakit ini. Oleh itu, penghasilan vaksin yang berkesan adalah penting untuk pencegahan dan kawalan wabak penyakit EV71. Penggunaan protein rekombinan daripada virus EV71 menawarkan satu alternatif kepada kaedah yang lebih berisiko seperti menggunakan virus yang telah dilemahkan atau tidak aktif. Dalam kajian sebelum ini, kami menggunakan protein VP1₁₋₁₀₀ yang merupakan sebahagian daripada protein VP1 virus EV71 yang digabungkan dengan protein pembawa. Protein tersebut menunjukkan tindak balas

imun yang kuat dalam arnab dewasa. Namun begitu, kajian berkenaan tidak mengemukakan persoalan tentang keberkesanannya dalam haiwan muda. Faktor ini adalah penting kerana kebanyakan pesakit yang dijangkiti EV71 adalah kanak-kanak berumur kurang daripada 5 tahun. Dalam kajian ini, kami mengkaji keberkesanan protein NPt-VP1₁₋₁₀₀ dalam memberi perlindungan terhadap jangkitan EV71 menggunakan model mencit muda yang dihasilkan baru-baru ini. Sebelum kajian dijalankan terhadap model mencit muda, kami menilai jenis tindak balas imun dalam mencit dewasa terhadap protein NPt-VP1₁₋₁₀₀. Protein itu menyebabkan penghasilan paras anti-IgG VP1 yang tinggi. Antigen VP1 yang telah dituliskan merangsang pengaktifan, penggandaan dan pembezaan splenosit yang diperolehi daripada mencit yang diimunisasi. Mencit itu juga menghasilkan paras IFN- γ yang tinggi. Setelah penentuan tindak balas imun terhadap protein NPt-VP1₁₋₁₀₀ dalam mencit dewasa dilakukan, kami mengkaji pula imunisasi dan cabaran virus dalam model mencit muda. Oleh kerana mencit mudah dijangkiti oleh EV71 sebelum mereka berumur 14 hari, hanya dua dos imunisasi diberikan. Meskipun IgG yang dihasilkan tidak mempunyai sifat neutralisasi, mencit yang diimunisasi masih dapat dilindungi secara tidak sepenuhnya daripada cabaran virus EV71. Mereka menunjukkan kadar hidup yang tinggi (47.4%) berbanding dengan kumpulan kawalan, dan pemerhatian terpenting ialah 50% daripada mereka pulih sepenuhnya daripada simptom kelumpuhan pada akhir kajian. Analisis histologi mereka menunjukkan tiada antigen virus EV71 dijumpai di otak dan saraf tunjang. Aras antigen yang dikesan di otot-otot kaki belakang mempunyai hubung kait secara langsung dengan kerosakan tisu dan simptom kelumpuhan. Kami juga melakukan kajian yang sama menggunakan

model hamster. Hamster mempunyai tempoh kerentanan terhadap EV71 yang lebih panjang berbanding mencit. Protein NPt-VP1₁₋₁₀₀ yang disuntik ke dalam hamster juga mempunyai kadar imunogenik yang tinggi. Keputusan daripada kajian menunjukkan bahawa imunisasi dengan protein NPt-VP1₁₋₁₀₀ dalam model mencit memberikan perlindungan separa kepada mereka terhadap jangkitan EV71. Oleh itu, protein NPt-VP1₁₋₁₀₀ mempunyai potensi yang tinggi sebagai vaksin untuk jangkitan EV71.



ACKNOWLEDGEMENTS

The valuable work cannot be accomplished just by chance or one person. First, I would like to express my deep and sincere gratitude to my project supervisor, Dr. Norazizah Shafee for her invaluable guidance and advises throughout my study and during thesis writing. I also express my deepest thanks to her for allowing me to be her student to pursue my master's degree in UPM. My appreciation also goes to my co-supervisor, Prof. Datin Paduka Dr. Khatijah Yusoff for her trust throughout the research. I am deeply indebted to Prof. Eric Stanbridge for his helpful suggestions and discussions.

A special thank is conveyed to Dr. Ong Kien Chai for guiding me on histological analysis and viral challenge study. I am also grateful to all my colleagues in the Virology Laboratory at the Faculty of Biotechnology and Biomolecular Sciences especially Jin Yew, Wei Boon, Kah Fai, Halimi, Eddie, Nurhasmin, Ain, Kak Hidayah, Wuan Ting, and from the Department of Pathology, Universiti Malaya: Woon Li, Yao Xian, Soon Hao, for their time, dedication and help. Also, many thanks to Tan Chow, Puan Rodiah and my friends for giving me encouragements and moral support throughout the project.

Last but not least, I would like to give my special gratitude to my parents, sisters and brothers for their encouragements, sympathy, understanding, and love.



I certify that a Thesis Examination Committee has met on **28th JUNE 2010** to conduct the final examination of **Ch'ng Wei Choong** on his thesis entitled **“Protective Efficacy Evaluation of NPt-VP1₁₋₁₀₀ Protein as a Candidate Vaccine against Enterovirus 71 Infections in Mouse Model”** in accordance with Universities and University Colleges Act 1971 and the Constitution of the Universiti Putra Malaysia [P.U.(A) 106] 15 March 1998. The Committee recommends that the student be awarded the **Master of Science**.

Members of the Examination Committee were as follows:

Noorjahan Banu Mohamed Alitheen, PhD

Lecturer

Faculty of Biotechnology and Biomolecular Sciences

Universiti Putra Malaysia

(Chairman)

Muhajir Hamid, PhD

Associate Professor

Faculty of Biotechnology and Biomolecular Sciences

Universiti Putra Malaysia

(Internal Examiner)

Syahida Ahmad, PhD

Lecturer

Faculty of Biotechnology and Biomolecular Sciences

Universiti Putra Malaysia

(Internal Examiner)

Chua Kek Heng, PhD

Associate Professor

Department of Molecular Medicine

Faculty of Medicine

Universiti Malaya

50603 Kuala Lumpur

Malaysia

(External Examiner)

BUJANG KIM HUAT, PhD

Professor and Deputy Dean

School of Graduate Studies

Universiti Putra Malaysia

Date: 12 August 2010



This thesis was submitted to the Senate of Universiti Putra Malaysia and has been accepted as fulfilment of the requirement for the degree of Master of Science. The members of the Supervisory Committee are as follows:

Norazizah Shafee, PhD

Senior Lecturer

Faculty of Biotechnology and Biomolecular Sciences

Universiti Putra Malaysia

(Chairman)

Khatijah Yusoff, PhD

Professor

Faculty of Biotechnology and Biomolecular Sciences

Universiti Putra Malaysia

(Member)

HASANAH MOHD GHAZALI, PhD

Professor and Dean

School of Graduate Studies

Universiti Putra Malaysia

Date: 12 August 2010



DECLARATION

I declare that the thesis is my original work except for quotations and citations which have been duly acknowledged. I also declare that it has not been previously, and is not concurrently, submitted for any other degree at Universiti Putra Malaysia or at any other institutions.

CH'NG WEI CHOONG

Date: 12 August 2010



TABLE OF CONTENTS

	Page
ABSTRACT	ii
ABSTRAK	iv
ACKNOWLEDGEMENTS	vii
APPROVAL	viii
DECLARATION	x
LIST OF TABLES	xiv
LIST OF FIGURES	xv
LIST OF ABBREVIATIONS	xvii
CHAPTER	
1 INTRODUCTION	1
2 LITERATURE REVIEW	3
2.1 Enterovirus 71	3
2.1.1 History of Enterovirus 71 Infections	3
2.1.2 Virus Classification	4
2.1.3 Virion Structure	5
2.1.4 Viral Genome	7
2.1.5 Viral Replication Cycle	9
2.2 Clinical Manifestations and Epidemiology	11
2.2.1 Clinical Manifestations of EV71 Infections	11
2.2.2 Epidemiology of EV71 Infections	12
2.3 Immune Responses	14
2.3.1 Th1 and Th2 Immune Responses	14
2.3.2 Immune Responses in Neonates	15
2.3.3 Immune Responses to EV71 Infections	16
2.4 Animal Model	18
2.5 Prevention and Control of EV71 Infections	20
2.5.1 Development of Antiviral Agents	20
2.5.2 Vaccine Development	22
2.5.3 Public Health Surveillance	24
2.6 Diagnostic Methods for EV71 Infections	26
2.7 Nucleocapsid Protein of Newcastle Disease Virus as a Carrier	28
3 MATERIALS AND METHODS	31
3.1 Source of pTrcHis2-NPfl and pTrcHis2-NPt-VP1 ₁₋₁₀₀ Plasmids	31
3.2 Source of VP1 Protein and Mouse-Adapted Enterovirus 71 Strain P5	31
3.3 Chemicals and Reagents	32



3.4	Preparation of Bacterial Clones Containing pTrcHis2-NPt-VP1 ₁₋₁₀₀	32
3.4.1	Preparation of Competent <i>E. coli</i> TOP10 Cells	32
3.4.2	Transformation	33
3.5	Screening of Bacterial Clones	33
3.5.1	Extraction of Plasmids	33
3.5.2	Amplification of NPt- VP1 ₁₋₁₀₀ DNA Fragments by PCR	34
3.5.3	Restriction Enzyme Digestion of Plasmid Constructs	35
3.6	Protein Expression	37
3.6.1	Expression of the NPfl and NPt-VP1 ₁₋₁₀₀ Recombinant Proteins	37
3.6.2	SDS-PAGE Gel Preparation	37
3.6.3	Protein Preparation on SDS-PAGE	38
3.6.4	Visualization of Protein Bands	38
3.6.5	Western Blotting and Immunodetection	39
3.6.6	Large Scale Production and Purification of NPfl and NPt-VP1 ₁₋₁₀₀ Recombinant Proteins	40
3.6.7	Determination of Purified NPfl and NPt-VP1 ₁₋₁₀₀ Protein Concentrations	41
3.7	Immunization Studies	42
3.7.1	Immunization of Adult Mice	42
3.7.2	Immunization of Newborn Mice	43
3.7.3	Immunization of Newborn Syrian Hamster	43
3.7.4	Determination of Anti-VP1 and Anti-NP Antibody Titers by Indirect Enzyme-Linked Immunosorbent Assay	44
3.8	Cellular Responses elicited by NPt-VP1 ₁₋₁₀₀ Protein Immunization	45
3.8.1	Preparation of Splenocytes	45
3.8.2	Monitoring of T-cell Proliferation by BrdU Cell Proliferation Assay	46
3.8.3	Determination of Cytokine Profiles by Th1/Th2 Cytokine Assay	47
3.9	Viral Challenge	49
3.10	Immunoblotting Analysis of Antibodies in Collected Sera	50
3.11	Histological Analysis	51
3.11.1	Preparation of Tissue Sections	51
3.11.2	Immunohistochemical Analysis	51
3.11.3	Hematoxylin and Eosin Staining	53
3.12	Neutralization Assay	54
3.13	Statistical Analysis	55
4	RESULTS	56
4.1	Screening of pTrcHis2-NPt-VP1 ₁₋₁₀₀ in <i>E. coli</i> TOP10 Bacteria	56
4.1.1	Restriction Enzyme Digestions and PCR	56
4.1.2	Expression of the NPfl and NPt-VP1 ₁₋₁₀₀ Recombinant Proteins	58



4.2	Production, Purification and Quantitation of the NPfl and NPt-VP1 ₁₋₁₀₀ Proteins	60
4.3	Humoral Immunity	64
4.4	Cellular-Mediated Immunity	67
4.4.1	Proliferation of Splenocytes in Response to VP1 Antigen	67
4.4.2	Production of Cytokines by VP1 Antigen-Induced Splenocytes	70
4.5	Viral Challenge in Newborn Mice	70
4.5.1	Survival Rate based on Different Protein Concentrations used in Vaccination	70
4.5.2	Body Weight and Paralysis Score of EV71 -Challenged Mice	72
4.6	Immune Responses and Cytokine Profiles after Challenge with EV71 ^{P5}	78
4.6.1	Immune Responses in Mice Challenged with EV71 ^{P5}	78
4.6.2	Production of Cytokines in Mice Challenged with EV71 ^{P5}	78
4.7	Immunoblotting Analysis of Antibodies in Mice Sera	80
4.8	Neutralization Assay	84
4.9	Histological Analysis	84
4.10	Viral Challenge Study in Hamster Model	91
5	DISCUSSION	99
6	CONCLUSION	112
	REFERENCES	114
	APPENDICES	130
	BIODATA OF STUDENT	134

